# GSTP1 as a therapeutic target for pancreatic cancer

> **NIH NIH R15** · NORTH DAKOTA STATE UNIVERSITY · 2020 · $433,934

## Abstract

PROJECT SUMMARY
Less than 9% of pancreatic ductal adenocarcinoma (PDAC) patients survive 5 years beyond diagnosis. A
primary reason for the low survival rate is that the best available treatments are not that effective for many
patients, and many tumors become resistant to them. A treatment approach that could sensitize tumor cells to
chemotherapy would be a major advance in the treatment of PDAC, the most deadly of the major cancer types
in the United States. The long term goals for this research are to enhance the biomedical research
environment at North Dakota State University and to identify clinically-relevant therapeutic targets to improve
treatment outcomes for PDAC patients. The objectives for this application are to provide training opportunities
for undergraduate and graduate students and to establish the tumor-promoting roles of the antioxidant enzyme
glutathione S-transferase pi 1 (GSTP1) in PDAC models. The central hypothesis is that inhibition of GSTP1
can sensitize PDAC cells to platinum-based chemotherapy and alter gene and metabolite expression profiles
that limit tumor growth. To test the central hypothesis, three Specific Aims are proposed: 1) Determine the
chemosensitizing effects of GSTP1 inhibition for PDAC cells, 2) Identify the gene expression changes
associated with GSTP1 inhibition in PDAC cells, and 3) Identify the metabolome changes associated with
GSTP1 inhibition in PDAC cells. For the first aim, cell culture and mouse models will be used to determine the
degree to which pharmacological and functional GSTP1 inhibition influence sensitivity to platinum-based
chemotherapy. For the second aim, our transcriptome data will be validated in GSTP1 knockdown PDAC cell
lines and in PDAC cells treated with a GSTP1 inhibitor. Functional assays will be performed to further identify
anti-tumor mechanisms associated with GSTP1 inhibition. For the third aim, targeted metabolomics will be
used to determine the metabolite expression changes in PDAC cells when GSTP1 function is impaired. The
approach is innovative because it will involve evaluating a molecular target that has not been studied before in
PDAC. The proposed research is significant because it is expected to advance the fields of PDAC treatment
and oxidative stress biology by establishing GSTP1 as a new therapeutic target for PDAC treatment and
revealing novel cellular responses to inhibition of this important antioxidant enzyme. The results from this
project are expected to expand understanding of how antioxidant enzymes can be targeted for
chemosensitization of tumor cells. Such knowledge has the potential to change the field of chemotherapy and
result in more effective cancer treatments. Given that treatment options for PDAC are currently lacking, there is
an urgent need to identify safe and more effective treatment approaches for this highly deadly disease. Finally,
this project will have a tremendous impact on the undergraduate and graduate students involved, and the
b...

## Key facts

- **NIH application ID:** 9965467
- **Project number:** 1R15CA249714-01
- **Recipient organization:** NORTH DAKOTA STATE UNIVERSITY
- **Principal Investigator:** Katie Reindl
- **Activity code:** R15 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $433,934
- **Award type:** 1
- **Project period:** 2020-08-01 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9965467

## Citation

> US National Institutes of Health, RePORTER application 9965467, GSTP1 as a therapeutic target for pancreatic cancer (1R15CA249714-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9965467. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*